The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Takeda Delivers Growth in All Focus Therapeutic Areas in April-December
Takeda Pharmaceutical notched up double-digit earnings growth in the first three quarters of FY2021, registering higher revenue in all its focus therapeutic areas, with its top product Entyvio (vedolizumab) expanding over 20%. In April-December, the Japanese drug juggernaut posted group…
To read the full story
Related Article
- Vyvanse Generics Drag Takeda Earnings; FY2025 Outlook Trimmed
October 31, 2025
- Takeda Sees Limited Tariff Exposure as US Remains Strategic Priority
July 31, 2025
- Takeda on Course to Stable Growth as Late-Stage Assets Near Market
May 9, 2025
- Takeda Ups Full-Year Guidance on Slower Vyvanse Generic Erosion
January 31, 2025
- Takeda’s Japan Sales Ratio Falls Below 10%, Global Biz Thrives in H1
November 1, 2024
- Takeda’s Operating Profit Dips by More than Half in FY2023
May 10, 2024
- Takeda’s April-December Sales Up 4.6%, but Flat at CER
February 2, 2024
- Takeda’s H1 Profit Tumbles on Write-Down Tied to Trial Setbacks, Outlook Slashed
October 27, 2023
- Takeda Q1 Sales Up 8.9%, Led by Key Product Growth and Weak Yen
July 28, 2023
- Takeda Logs Record Sales, Breaks 4 Trillion Yen Mark in FY2022
May 12, 2023
- Takeda Logs Double-Digit Growth, Led by Core Products and Weaker Yen
February 3, 2023
- Takeda’s H1 Sales Up 10% Backed by Robust Mainstays, Hefty FX Gains
October 28, 2022
- Takeda’s Q1 Sales Up 2.4% Despite Diabetes Divesture Last Year, Gets Hefty FX Gains
July 29, 2022
- Takeda’s FY2021 Sales Up 11.6%; Weak Yen Tailwind for Revenue, but Drags Profits
May 12, 2022
- Takeda’s H1 Sales Log Two-Digit Growth Driven by Global Brands, FDA Wraps Up Plant Re-Inspection
October 29, 2021
- Takeda’s Q1 Sales Rise on Diabetes Divestiture; Plant Re-Inspection Results Expected Late October
August 2, 2021
BUSINESS
- Takeda Taps Halozyme’s Delivery Tech to Develop New Entyvio SC Formulation
January 13, 2026
- Japan Heart Failure Drug Market Seen 1.5-Fold Growth by 2030: Fuji Keizai
January 13, 2026
- Daito Secures China Approval for EquMet Generic
January 13, 2026
- Japan Ethical Drug Sales Edge Up 0.4% in November: Crecon
January 13, 2026
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…